Skip to main content Skip to search Skip to main navigation

EC: Fifth Notified Body according to IVDR

The European Commission (EC) designated the German company TÜV Rheinland as a Notified Body under the In Vitro Diagnostics (IVDR) Regulation on 1 December 2020.

The IVDR will replace the currently valid IVD Directive (98/79/EC) as of 26 May 2022. With the new IVDR, manufacturers will have to perform conformity assessments for considerably more products.  

Dr. Wilma Hartung, Managing Director Medical Devices at TÜV Rheinland, sees a significant workload coming up for the Notified Bodies: Many manufacturers of in-vitro diagnostics have to be certified for the first time. 

The European Association Medical devices of Notified Bodies (Team-NB) is also concerned. In a position paper published on 25 November 2020, the Team-NB states that Notified Bodies will only support compliance with the current deadlines if the following conditions are met by the end of 2020: 

  • The tools for conducting conformity assessments (e.g. expert:in panels, relevant MDCG guidance documents for classification, performance evaluation etc.) must be available and ready for use.   
  • At least half of the currently existing Notified Bodies should be designated according to the IVDR. Currently, there are five Notified Bodies, but after 31 December 2020 there will be only four, due to the brexit, unless more are added.  

Furthermore, the difficulty to perform QMS audits on site due to Covid-19 is addressed. Team-NB requires a decision on the deadline by the end of 2020 if the conditions cannot be met. 


Sources: 

TÜV Rheinland LGA Products GmbH: TÜV Rheinland: Notified Body for In-Vitro Diagnostics 

EC: NANDO 

Team-NB: Team-NB consideration paper on IVDR Date of Application 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

The EMA has published a new Q&A paper on technical and organisational measures to prevent microbial contamination of non-sterile medicinal products.
Read more
Why is import authorisation necessary for medicinal products entering the EU?

Why is import authorisation necessary for medicinal products entering the EU?

Read more
When APS Fail and First Air is at Risk

When APS Fail and First Air is at Risk

At the PDA Good Aseptic Manufacturing Conference 2026, Alberto Gonzales (Takeda) discussed challenges and practical solutions related to aseptic process simulations (APS). Anna Campanella (Takeda) and Hussein Bachir (Franz Ziel) explored how first air protection in aseptic processing can be compromised by equipment design, glove interventions, and operator activities.
Read more
FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
EMA: Revised Q&A MRA EU-USA

EMA: Revised Q&A MRA EU-USA

The EMA has updated its Questions and Answers on the EU-US Mutual Recognition Agreement (MRA). The update follows the completion of the FDA's assessment of all EU authorities responsible for GMP inspections of veterinary medicinal products on 29 May 2026.
Read more
WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO published a draft consultation document on regulatory oversight of disposal of medical products throughout the lifecycle.
Read more
Previous
Next